We did this by stimulating airway fibroblasts with a 1 ng/ml dose of recombinant IL-1α, IL-1β or IL-33 for 24 hours and then assessed the release of inflammatory mediators known to be involved in chronic inflammation, and airway hyperresponsiveness in asthma7,21. This evidence concerns the gene IL1A and airway hyperresponsiveness.